Followers | 3350 |
Posts | 86065 |
Boards Moderated | 5 |
Alias Born | 10/05/2005 |
Friday, June 26, 2020 11:31:39 PM
With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke™. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare
Give Me A Follow If You Want To Consistently Find Winners!
Click Here:
https://investorshub.advfn.com/boards/profilea.aspx?user=61470
Please do your own DD...All my posts are my opinion only!
Recent XERS News
- Xeris to Participate in Upcoming Investor Conferences • Business Wire • 08/22/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:06:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/08/2024 08:27:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:15:47 AM
- Xeris Biopharma Reports Second Quarter 2024 Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:22:39 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:14:16 PM
- Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 • Business Wire • 07/25/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 11:14:32 AM
- Xeris Biopharma Announces CEO Succession Plan • Business Wire • 07/08/2024 11:00:00 AM
- Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 07/03/2024 05:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:19:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:15:27 PM
- Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024 • Business Wire • 06/03/2024 11:00:00 AM
- Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) • Business Wire • 05/30/2024 11:30:00 AM
- Xeris to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:14:33 AM
- Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events • Business Wire • 05/09/2024 11:00:00 AM
- Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics • Business Wire • 05/06/2024 11:00:00 AM
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 05/02/2024 11:00:00 AM
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 08:05:00 PM
- Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/02/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:19:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:10:13 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM